SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) SVP Dragan Cicic sold 6,933 shares of SELLAS Life Sciences Group stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $19.18, for a total value of $132,974.94. Following the sale, the senior vice president owned 557,361 shares in the company, valued at $10,690,183.98. This trade represents a 1.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
SELLAS Life Sciences Group Stock Down 8.1%
Shares of NASDAQ SLS traded down $1.20 during trading hours on Friday, reaching $13.66. The stock had a trading volume of 15,361,567 shares, compared to its average volume of 7,646,582. The firm has a 50-day moving average of $11.11 and a 200-day moving average of $8.99. SELLAS Life Sciences Group, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $24.89.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05).
Hedge Funds Weigh In On SELLAS Life Sciences Group
Hedge funds and other institutional investors have recently bought and sold shares of the company. Dagco Inc. grew its position in SELLAS Life Sciences Group by 8.4% in the 3rd quarter. Dagco Inc. now owns 1,336,449 shares of the company’s stock valued at $16,452,000 after buying an additional 104,016 shares during the last quarter. Goldman Sachs Group Inc. raised its position in SELLAS Life Sciences Group by 86.0% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,088,136 shares of the company’s stock worth $13,395,000 after buying an additional 503,101 shares during the last quarter. Bank of America Corp DE raised its position in SELLAS Life Sciences Group by 535.7% during the 1st quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock worth $2,714,000 after buying an additional 540,748 shares during the last quarter. Wellington Management Group LLP raised its position in SELLAS Life Sciences Group by 73.2% during the 2nd quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock worth $8,816,000 after buying an additional 252,531 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of SELLAS Life Sciences Group in the 2nd quarter worth $7,823,000. 17.38% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research firms have commented on SLS. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, October 15th. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, SELLAS Life Sciences Group has an average rating of “Hold” and an average price target of $10.00.
View Our Latest Stock Analysis on SLS
Key Headlines Impacting SELLAS Life Sciences Group
Investors following SLS have been watching these headlines:
- Neutral Sentiment: A Seeking Alpha article upgraded its rating after describing a “big win,” while noting areas of uncertainty. The headline provided does not specify the underlying development, limiting what can be concluded about its likely effect on the shares. Seeking Alpha article
- Neutral Sentiment: A report says a recent filing has prompted speculation among retail investors that SELLAS may have greater buyout leverage. That is an investor interpretation, not a confirmed acquisition process or offer. MSN report on the offering and buyout speculation
- Negative Sentiment: The $13 offering price and issuance of millions of new shares increase dilution risk for current shareholders. The discounted financing triggered a sharp selloff, outweighing the benefit of the added cash in the near term. StreetInsider offering report
About SELLAS Life Sciences Group
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.
Featured Articles
- Five stocks we like better than SELLAS Life Sciences Group
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
